A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study of MC002

Clinical trial NCT07726212 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07726212
Sponsor: Hangzhou MacroLink Biopharmaceutical LLC
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Esophageal Cancer Advanced Lung Cancer

Start date: 2026-09-01
Primary completion: 2027-12-01
Enrollment: 143

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.